Loading stock data…
EMBC
$9.23+0.08 (+0.87%)
Market ClosedLast close May 1
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Embecta Corp. in the Healthcare sector is trading at $9.23. The stock is currently near its 52-week low of $8.47, remaining 20.7% below its 200-day moving average. Technical signals show neutral RSI of 49 and bearish MACD signal, explaining why EMBC maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 49) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$9.23
Potential Upside
244.6%
Whystock Fair Value$31.81
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection device...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$545.41M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
3.90
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.10
Div Yield
Strong income play. Yield provides a meaningful total return floor.
651.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-22.75%
Volume
Today's trading volume
727,468
Recent News
How The Embecta (EMBC) Story Is Shifting As Targets Trim While Fair Value Holds
Analysts recently trimmed Embecta price targets by about US$2 to US$3, even as the fair value estimate stayed anchored at US$15. These adjustments reflect a split view, with bullish voices treating the move as a technical reset and more cautious analysts reading it as a signal that near term uncertainty may cap upside for now. As you read on, you will see how this evolving narrative could shape the way you track Embecta from here. Analyst Price Targets don't always capture the full story...
Is Embecta (EMBC) One of the 10 Healthcare Stocks with Highest Dividends?
Embecta Corp. (NASDAQ:EMBC) is included among the 10 Healthcare Stocks with Highest Dividends. On April 13, Mizuho lowered its price recommendation on Embecta Corp. (NASDAQ:EMBC) to $12 from $14. It reiterated a Neutral rating on the shares. The change came as the firm adjusted estimates and targets across several medical devices and diagnostics names ahead […]
How The Embecta (EMBC) Investment Story Is Shifting As Fair Value And Expectations Reset
Embecta’s implied fair value has been reset from US$16.67 to US$15.00, giving you a fresh reference point for where analysts now see the stock. That reduction lines up with recent commentary that takes a more cautious stance, as price targets are trimmed to better match updated assumptions on the company’s outlook. Read on to see what this reset might mean for your own view and how to track the story as analyst expectations continue to evolve. Analyst Price Targets don't always capture the...
Should You Investigate Embecta Corp. (NASDAQ:EMBC) At US$8.88?
Embecta Corp. ( NASDAQ:EMBC ), might not be a large cap stock, but it saw significant share price movement during...
Embecta to Acquire Owen Mumford to Expand Drug-Delivery Portfolio
EMBC to acquire Owen Mumford for up to $199.4M, aiming to expand beyond diabetes into high-value drug delivery and boost long-term growth.